The Association of American Cancer Institutes and the White House Cancer Moonshot Task Force are developing a new method for funding research at academic cancer centers through private investment and philanthropy.
Nature published an editorial supporting Kids vs. Cancer's bill to increase support for pediatric clinical trials.
Greg Curt died last Sunday. For us in oncology, this one was especially personal. He was a wonderful, generous young man. Greg was a beloved friend and colleague. He was an accomplished cancer researcher and leader in oncology who died of the disease we treat.
League tables like those published by U.S. News and World Report should probably be taken with a pinch of salt in any case, but it is the self-marketing of these tables that is just a bit problematic.
The U.S. News & World Report rankings of the best cancer hospitals for 2016 brought no great surprises. The top four remained unchanged from last year:
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A phase III study evaluating Gazyva (obinutuzumab) plus CHOP chemotherapy in people with previously untreated diffuse large B-cell lymphoma did not meet its primary endpoint of progression-free survival compared to Rituxan (rituximab) plus CHOP chemotherapy, according to Genentech, a member of the Roche Group.
A phase III study evaluating Gazyva (obinutuzumab) plus CHOP chemotherapy in people with previously untreated diffuse large B-cell lymphoma did not meet its primary endpoint of progression-free survival compared to Rituxan (rituximab) plus CHOP chemotherapy, according to Genentech, a member of the Roche Group.
Results from a phase III trial of patients with metastatic colorectal cancer demonstrated that Erbitux (cetuximab) plus FOLFOX improved outcomes—including progression-free survival, overall survival and best overall response rate—when compared with FOLFOX alone.
Positive results from a phase III trial in advanced colorectal cancer showed that Xilonix-treated patients with advanced disease and multiple symptoms known to inversely correlate with overall survival experienced a 76 percent relative increase in clinical response rate after eight weeks of therapy compared to placebo, at 33 percent vs. 19 percent, respectively (p=.0045).
